Cash Flow from Operating Activities: A company's cash flows from operations.
Neumora Therapeutics, Inc. (NMRA) had Cash Flow from Operating Activities of $-206.44M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-59.45M |
|
-- |
|
-- |
|
$58.48M |
|
$-58.48M |
|
$-0.97M |
|
$-59.45M |
|
$-59.45M |
|
$-59.45M |
|
$-59.45M |
|
$-59.45M |
|
$-59.45M |
|
$-58.48M |
|
$-57.40M |
|
163.39M |
|
163.39M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$190.54M |
|
$0.04M |
|
$0.51M |
|
$191.05M |
|
$32.45M |
|
$54.53M |
|
$54.73M |
|
$87.18M |
|
$103.87M |
|
$103.87M |
|
$103.87M |
|
174.26M |
|
| Cash Flow Statement Financials | |
|
Cash Flow from Operating Activities |
$-206.44M |
$168.52M |
|
$77.09M |
|
$143.36M |
|
$182.53M |
|
$39.17M |
|
$29.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.87 |
|
-- |
|
-- |
|
0.34 |
|
0.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-206.22M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-57.23% |
|
-57.23% |
|
-31.12% |
|
-37.53% |
|
$0.60 |
|
$-1.26 |
|
$-1.26 |
|